Zepbound with Ongoing Care A dual-pathway GLP-1/GIP injectable with the most potent metabolic and weight-loss benefits
or palpitations that worsen progressively over several days despite hydration and rest
How it Works CJC-1295 stimulates growth hormone-releasing hormone (GHRH), while Ipamorelin mimics ghrelin to enhance natural growth hormone release, helping to regulate metabolism and cellular repair
Typical Starting Protocol Sermorelin: 100-200 mcg subcutaneous CJC-1295 (no DAC / Mod GRF 1-29): 100-200 mcg subcutaneous Both injected simultaneously, same syringe or adjacent sites, at bedtime Frequency: 5 nights per week (Monday through Friday), cycling off weekends to reduce pituitary desensitization risk Total GHRH-equivalent stimulus per injection in the stack is therefore 200-400 mcg, which is within the dose range studied in sermorelin monotherapy trials [1] and in the Jett pharmacokinetic study for CJC-1295 [2]
In 1958, Fritz discovered that L-carnitine played a crucial role in the oxidation of long-chain fatty acids in heart and muscle tissues
Voltage-gated sodium channels in taste bud cells
